The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
More than 10% of U.S. adults use GLP-1 drugs like Ozempic and Wegovy, but one in seven microdose for longevity without major weight loss or side effects, per Evidation survey. Biohackers and clinics like AgelessRx promote it for reducing inflammation and chronic disease risks. Yet experts caution on unproven claims and sourcing risks.
A venomous desert lizard, the Gila monster, holds a surprising key to one of medicine's biggest breakthroughs: Ozempic. Its venom revealed exendin-4, a stable GLP-1 mimic that paved the way for transformative diabetes therapies. This unlikely origin story highlights nature's role in modern metabolic health.
As GLP-1 medication use surges, a Weight Watchers report reveals medication alone isn't enough for lasting weight loss. Weight Loss Buddy emerges as a vital tool, combining AI-driven guidance and peer accountability to boost adherence and outcomes. This shift highlights the need for behavioral infrastructure in obesity treatment.
Charles Barkley's noticeably slimmer figure courtside during March Madness 2026 has sparked widespread speculation: Is Ozempic behind his weight loss? The NBA legend dropped nearly 90 pounds using GLP-1 drugs like Mounjaro and Zepbound, combined with diet and exercise. Fans are stunned, but Barkley credits hard work over hype.
Researchers at the University of Colorado Boulder have identified para-tyramine-O-sulfate (pTOS) in python blood, a compound that skyrockets after meals to suppress appetite and support metabolic health. Unlike GLP-1 drugs like Ozempic, pTOS drove weight loss in mice without gastrointestinal issues or muscle wasting. This breakthrough, published in Nature Metabolism, hints at new therapies inspired by python metabolism.
Natco Pharma is shaking up India's weight-loss drug market with its generic semaglutide priced at just ₹1,290 per month—90% cheaper than Novo Nordisk's Ozempic. Launching Saturday after patent expiry, this move invites competition from Sun Pharma, Dr Reddy's, and others. Patients gain affordable access to this GLP-1 powerhouse for weight management and diabetes.
Popular GLP-1 drugs like semaglutide and tirzepatide offer heart health benefits for type 2 diabetes patients, but stopping them may reverse these gains. A Washington University study of over 333,000 veterans revealed up to 22% higher risk of heart attacks and strokes after discontinuation. Continuous use provides up to 18% risk reduction—here's what it means for long-term treatment.
Boston Public Employee Committee rejects Mayor Wu's push for immediate prior authorization on GLP-1 weight loss drugs, proposing a six-month delay instead. Amid skyrocketing costs projected at $47.4M for FY27, unions demand a contract extension. Tensions rise as some unions favor cuts to avoid layoffs.
Eli Lilly announced that its next-generation obesity drug retatrutide met both primary and secondary goals in its first late-stage trial for type 2 diabetes patients. The drug achieved significant A1c reductions of 1.7% to 2% and impressive weight loss of up to 16.8% at 40 weeks. This marks a promising advancement for patients struggling with both blood sugar control and weight management.
